

가가

Effect of a Single Tetanus Toxoid in Korean Adults with Low Tetanus Antibody Titers

Yoo Sang Yoon, M.D., Hyun Woong No, M.D., Seung Ho Kim, M.D., Wen Joen Chang, M.D.¹, Ho Shik Shim, M.D.

Purpose: The determination of tetanus prophylaxis according to patients' memories of past immunization is inaccurate. However, by using the Tetanus Quick Stick test, it is possible to select Korean adults with low tetanus antibody titers and to perform tetanus prophylaxis in the emergency department. In 1996, Ha reported that tetanus toxoid injection into healthy Korean adults revealed significant differences between the tetanus antibody titers at the beginning and the tetanus antibody titers after 1 week. Our purpose is to determine the effect of a single tetanus toxoid in Korean adults with low tetanus antibody titers.

Methods: Blood samples were taken from 44 volunteers for a period of 6 weeks. All samples were analyzed using the Tetanus IgG ELISA (enzyme-linked immunosorbent assay) method.

Results: The results for tetanus antibody titers at the beginning and after 1 week, 2 weeks, 4 weeks, and 6 weeks were 0.04 ± 0.05 IU/mL, 1.22 ± 3.63 IU/mL, 4.99 ± 7.36 IU/mL, 8.36 ± 11.10 IU/mL and 6.59 ± 9.21 IU/mL respectively. There was a statistically significant difference between the tetanus antibody titers at the beginning and the tetanus antibody titers after 2 weeks. There was no statistically significant difference between the tetanus antibody

titers after 2 weeks and 6 weeks. After 4 weeks, all subjects' tetanus antibody titers were at the protective level.

Conclusions: A single tetanus toxoid injection is effective in Korean adults with low tetanus antibody titers.

Key Words: Tetanus, Tetanus toxoid, Immunization

Department of Emergency Medicine, Yonsei University College of Medicine, Seoul, Korea, Department of Emergency Medicine, Sung Ae Hospital, Seoul, Korea

가가¹⁾, 1981
 DPT, DTaP, 2, 4, 6, 4~6, 5
 3, 18, 10, 가
²⁾
^{3,4)} 2000, 가, 10, 가, 50, 가
⁴⁾ 2001, Kang³⁾, 가, 가가, 가
 , 2004, 5, 가, 가

ing substrate solution 20
(stop solution)
450 nm
가 0.1 IU/mL

가 2
(p<0.05). 2~6
4 44
IU/mL)

가
가(0.1
4
가가
(Fig. 3).

3.

SPSS for Windows 11.5

가 one-
way ANOVA Tukey
가 65 20
가 Kruskal-Wallis
p 0.05

65 8
가 가 (p<0.05). 4
8 가(0.1 IU/mL)
(Table 3). 4

가가
(Fig. 4).

20 5
가 가 (p<0.05)(Fig. 5). 2
5 가 (Table 4).



20 53 TQS
7 46
6 5 ELISA
가 0.2 IU/mL 2
가 0.2 IU/mL 44
24 20 46.9±
16.6(24~78) 20~29 5
, 30~39 18 , 40~49 1 , 50~59 1 ,
60~64 11 , 65 8
44
가 2
(p<0.05)(Fig. 2). 2~6 가
4 44 가(0.1
IU/mL) (Table 1). 4
6 가가
(Fig. 2).
65 36




Fig. 2. Tetanus antibody titers in all subjects (N=44).

*p<0.05
outliers
extreme point

Table 1. Tetanus antibody titers in all subjects (N=44)

	Mean ± SD	Minimum	Maximum
Beginning (IU/mL)	0.04 ± 0.05	0.00	0.17
1 week (IU/mL)	1.22 ± 3.63	0.00	19.16
2 weeks (IU/mL)	4.99 ± 7.36*	0.04	32.05
4 weeks (IU/mL)	8.36 ± 11.10*	0.25	53.41
6 weeks (IU/mL)	6.59 ± 9.21*	0.18	38.33

N: number, SD: standard deviation
*p<0.05

30 18
 가 2
 (p<0.05). 2~6
 가 (Fig. 6). 2 18
 가(0.1 IU/mL) (Table 5).




Fig. 3. Tetanus antibody titers in less than 65 years old subjects (N=36).
 *p<0.05
 outliers
 extreme point

Clostridium tetani
 tetanoplasmin




Fig. 4. Tetanus antibody titers in more than 65 years old subjects (N=8).
 *p<0.05
 extreme point

Table 2. Tetanus antibody titers in less than 65 years old subjects (N=36)

	Mean ± SD	Minimum	Maximum
Beginning (IU/mL)	0.04 ± 0.05	0.00	0.17
1 week (IU/mL)	1.48 ± 3.98	0.00	19.16
2 weeks (IU/mL)	5.94 ± 7.82*	0.04	32.05
4 weeks (IU/mL)	8.87 ± 11.42*	0.25	53.41
6 weeks (IU/mL)	7.23 ± 9.65*	0.18	38.33

N: number, SD: standard deviation

*p<0.05

Table 3. Tetanus antibody titers in more than 65 years old subjects (N=8)

	Mean ± SD	Minimum	Maximum
Beginning (IU/mL)	0.05 ± 0.05	0.00	0.13
1 week (IU/mL)	0.06 ± 0.08	0.00	0.22
2 weeks (IU/mL)	0.70 ± 1.11	0.09	3.29
4 weeks (IU/mL)	4.95 ± 8.51	0.45	20.10
6 weeks (IU/mL)	2.19 ± 3.09	0.29	7.59

N: number, SD: standard deviation

glycin 가 GABA 가

13,14)

14

15)




Fig. 5. Tetanus antibody titers between 20 and 29 years old (N=5).
* $p < 0.05$

1940

1988 10

65

1947 10

가

가

16), 1927

0.39

4)

가

가




Fig. 6. Tetanus antibody titers between 30 and 39 years old (N=18).
* $p < 0.05$
outliers
extreme point

Table 4. Tetanus antibody titers between 20 and 29 years old (N=5)

	Mean ± SD	Minimum	Maximum
Beginning (IU/mL)	0.04 ± 0.06	0.00	0.15
1 week (IU/mL)	0.66 ± 0.74	0.02	1.80
2 weeks (IU/mL)	5.45 ± 7.21	0.24	17.26
4 weeks (IU/mL)	11.39 ± 12.04	0.43	29.39
6 weeks (IU/mL)	8.67 ± 8.28	0.53	18.79

N: number, SD: standard deviation

Table 5. Tetanus antibody titers between 30 and 39 years old (N=18)

	Mean ± SD	Minimum	Maximum
Beginning (IU/mL)	0.05 ± 0.06	0.00	0.17
1 week (IU/mL)	2.72 ± 5.40	0.01	19.16
2 weeks (IU/mL)	8.90 ± 8.90*	0.13	32.05
4 weeks (IU/mL)	11.80 ± 13.38*	1.09	53.41
6 weeks (IU/mL)	10.01 ± 11.67*	1.10	38.33


N: number, SD: standard deviation

* $p < 0.05$

가
 가 가 가
^{3,4)} 15 가 44
 30~40% , , 20 65
 65 가 가
¹⁷⁻¹⁹⁾ 2001 ³⁾ 가 가
 0.1 IU/mL 20 42%, 30
 75% ELISA
 가 0.1 IU/mL
 0.15 IU/mL 0.17 IU/mL
^{16,20,21)}
 가 .
 가 1 가가
 4 44
 가 가 0.17 IU/mL 4
 가 .
 1996 Ha ⁴⁾ 28 20
 가 10.18
 IU/mL , 1 가
 3.
 가 8.32 IU/mL , 2 가
 가 가가
 가 Ha ⁴⁾ 가
 가 .
 가 .
 1997 Kumar ¹⁶⁾ 65
 가가
 . 65 4 , 6
 8.87 IU/mL, 7.23 IU/mL ,
 65 4 , 6 4.95
 IU/mL, 2.19 IU/mL
 ,
 (Table 2,3). 65
 가 .
 가 가 .
 , 65 1
 가 .
 Lee ²²⁾
 가 .
 가 .
 Fig. 2 Fig. 3
 6
 1 6
 가 가 가



가가
 1 가가
 44
 1. 2 가가
 2. 2, 4, 6 가
 3. 가 가
 4 가
 가가
 1
 가



1. Centers for Disease Control and Prevention. Tetanus Surveillance -United States 1995-1997. MMWR 1998;47(SS-2):1-13.
2. Available at: http://www.cdc.go.kr/webcdc/menu05/1_prevention/1_prevention.jsp Accessed May 18, 2005.
3. Kang JH, Hur JK, Kim JH, Lee KI, Park SE, Ma SH. Age related serosurvey of immunity to tetanus in Korean populations. Korean J Infect Dis 2001;33:104-11.
4. Ha YR, Goo HD, Kim SW, Jang SJ, Lee HS, Shim HS, et al. Antitetanus antibody titer after toxoid injection. J Korean Soc Emerg Med 1996;7:202-6.
5. Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertusis: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40:1-8.
6. Giangrasso J, Smith RK. Misuse of tetanus immunoprophylaxis in wound care. Ann Emerg Med 1985;14:573-9.
7. Schatz D, Ellis T, Ottendorfer E, Jodoin E, Barrett D, Atkinson M. Aging and the immune response to tetanus toxoid: diminished frequency and level of cellular immune reactivity to antigenic stimulation. Clin Diagn Lab

- Immunol 1998;5:894-6.
8. Mayorga C, Torres MJ, Corzo JL, Alvarez J, Garcia JA, Rodriguez CA. Immediate allergy to tetanus toxoid vaccine: determination of immunoglobulin E and immunoglobulin G antibodies to allergenic proteins. *Ann Allergy Asthma Immunol* 2003;90:238-43.
 9. Yoon YS, Kim EC, Lee WH, Chung SW, Yi JH, Park IC, et al. Utility of Tetanos Quick Stick test for Selective Tetanus Prophylaxis. *J Korean Soc Emerg Med* 2004;15:95-101.
 10. Ozturk A, Goahmetoglu S, Erdem F. Tetanus antitoxin levels among adults over 40 years of age in Central Anatolia, Turkey. *Clin Microbiol Infect* 2003;9:33-8.
 11. Tamy S, Esther M, Yoram S. Immunologic response to a single tetanus toxoid in older people. *J Am Geriatr Soc* 2000;48:949-51.
 12. Shohat T, Marva E, Sivan Y, Lerman I, Mates A, Cohen A. Immunologic response to a single dose of tetanus toxoid in older people. *J Am Geriatr Soc* 2000;48:949-51.
 13. Ha YR, Kim OJ, Choi OK, Goo HD, Kim SW, Park IC, et al. A study on the effectiveness of antitetanus immunoglobulin. *J Korean Soc Emerg Med* 1994;5:258-62.
 14. Cavuslu S, Oncul O, Altunay H, Ozsoy MF, Kocak N. Seroprevalence of tetanus antibody in Turkish population and effectiveness of single dose tetanus toxoid. *Eur J Clin Microbiol Infect Dis* 2003;22:431-3.
 15. Kefer MP. Tetanus. *Am J Emerg Med* 1992;10:445-8.
 16. Kumar A, William R, Vibhu N, Charles A. Immunologic response to tetanus toxoid in geriatric patients. *Ann Emerg Med* 1997;30:459-62.
 17. Ruben FL. Antitoxin responses in the elderly tetanus-diphtheria immunization. *Am J Epidemiol* 1987;108:145-9.
 18. Gergen PJ, McQuillan GM, Kiely M. A population-based serologic survey of immunity to tetanus in the United States. *N Engl J Med* 1995;332:761-6.
 19. Kumar A, William R, David L, Charles A. Immunologic response to tetanus toxoid in the elderly: one-year follow-up. *Ann Emerg Med* 1998;32:155-60.
 20. McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. *Ann Intern Med* 2002;136:660-6.
 21. Hsu SS, Groleau G. Tetanus in the emergency department: a current review. *J Emerg Med* 2001;20:357-65.
 22. Lee YH, Han DJ. A clinical analysis of tetanus. *J Korean Surg Soc* 1991;40:77-87.